Treatment of multiple keratoacanthomas with erlotinib

Reid, Duncan; Guitart, Joan; Agulnik, Mark; Lacouture, Mario E.

doi:10.1007/s10147-010-0047-8

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acitretin (0.5–1 mg/kg) is usually proposed as first-line treatment [ 19 – 21 ]. Methotrexate [ 22 – 24 ], topical 5-fluorouracil [ 21 ], cyclophosphamide [ 25 , 26 ], and erlotinib [ 27 , 28 ] are other reported therapeutic options. Here, acitretin combined with a surgical procedure was used successfully.…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin

Mascitti

Masson

Brunet‐Possenti

et al. 2019

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Keratoacanthomas (KA) are common cutaneous skin tumors originating from the hair follicles. Unlike squamous cell carcinoma, KA can regress spontaneously and have a benign evolution. Solitary KA is the most common form but familial multiple KA (Ferguson–Smith type), genetically predisposed KA (such as in xeroderma pigmentosum, or Muir–Torre syndrome), or sporadic multiple eruptive KA (Grzybowski type) have been described. Generalized eruptive KA of Grzybowski (GEKA) is a rare condition (around 40 reported cases). The pathophysiology is still unclear. Human papillomavirus (HPV) has been detected in sporadic KA but the presence of HPV39 has never been reported, to our knowledge, in GEKA. Case Report GEKA in an 80-year-old woman was successfully treated with acitretin (0.5 mg/kg/day) combined with surgical removal of the largest lesions. Treatment was well tolerated and led to decreased pruritus and tumor regression within 6 months. The presence of HPV39 was detected in a lesion by polymerase chain reaction and Sanger sequencing. No genetic alteration was found, in particular in the genes usually altered in squamous cell carcinoma (including NOTCH1 , NOTCH2 , CDKN2A , TP53 ). Conclusion We report a case of GEKA associated with the presence of HPV39 and the successful use of acitretin combined with surgical removal of the larger lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin

Mascitti

Masson

Brunet‐Possenti

et al. 2019

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…The frequency of skin eruptions observed during anti-EGFR treatment also highlights the importance of this receptor to skin integrity. It is perhaps unsurprising that anti-EGFR drugs have now been reported to induce regression of both solar keratoses 87 and widespread keratoacanthomas, 88 as well as reported benefit in severe palmoplantar keratoderma. 89 These studies may herald the introduction of anti-EGFR therapies into routine dermatology practice over the years to come.…”

Section: Discussionmentioning

confidence: 99%

The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target

Gaffney

Soyer

Simpson

2013

Australasian Journal of Dermatology

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) of the skin is an increasingly common diagnosis worldwide. Together with precursor lesions, SCC carry a significant morbidity, particularly in regions with high solar UV radiation levels. Advanced lesions are locally or sometimes widely metastatic and may be resistant to treatment. Drugs targeting the epidermal growth factor receptor (EGFR) are currently the only significant non-surgical option for advanced SCC beyond radiotherapy and conventional chemotherapy. The role of the EGFR in skin cancer is described and the outcomes of targeted anti-EGFR therapy published to date are summarised. The future of anti-EGFR targeted therapies in the treatment of skin cancer is discussed. Targeted molecular therapies are becoming increasingly widespread and an understanding of the evidence for their use as well as their side effect profile is important in order to offer patients informed and current advice.

show abstract

“…KA have been successfully treated with the EGFR inhibitor erlotinib suggesting that EGFR activation is important in the development of KA . New insight into the pathogenesis of KA has been gleaned from the side effect profiles of some of the new biological kinase inhibitors.…”

Section: Discussionmentioning

confidence: 99%

EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study

2013

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) and MYC genomic aberrations have been described in cutaneous squamous cell carcinoma (SCC) but have not been widely investigated in keratoacanthoma (KA). EGFR and MYC were evaluated by fluorescence in situ hybridization and immunohistochemistry in 8 verrucae, 19 involuting KA (IKA), 23 classic KA (CKA), 6 atypical KA (AKA) and 19 SCC. Increased EGFR gene copy number was seen in 9 of 23 CKA and 14 of 19 SCC (p = 0.03). Increased MYC gene copy number was observed in 7 of 23 CKA and 17 of 19 SCC (p = 0.0001). MYC gene amplification was more common in SCC than CKA (p = 0.005), while EGFR gene amplification was rare and not significant. MYC protein overexpression was identified in 6 of 23 CKA and 14 of 19 SCC (p = 0.005). There was no statistical difference in EGFR protein overexpression in SCC and CKA (p = 0.06). EGFR and MYC aberrations were rare in IKA. AKA showed EGFR and MYC anomalies at an incidence intermediate between CKA and SCC. EGFR and MYC gene copy number aberrations are more common in SCC than KA. The incidence of aberrations parallels the degree of cytologic atypia in KA.

show abstract

Treatment of multiple keratoacanthomas with erlotinib

Cited by 8 publications

References 8 publications

Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin

Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin

The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target

EGFR and MYC gene copy number aberrations are more common in squamous cell carcinoma than keratoacanthoma: a FISH study

Contact Info

Product

Resources

About